Article Abstract

Can EGFR mutation status evolve with chemotherapy?

Authors: Eric S. Kim, David J. Stewart, Alok A. Khorana


Epidermal growth factor receptor (EGFR) inhibition by oral tyrosine kinase inhibitors (TKIs) and platinum-based chemotherapy are important treatment strategies for advanced non-small-cell lung cancer (NSCLC). However, a significant number of patients have tumors that are intrinsically resistant to chemotherapy and/or TKIs, and even those who respond initially eventually develop acquired resistance.